| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3285248 | Clinical Gastroenterology and Hepatology | 2007 | 4 Pages |
Abstract
Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of non-small-cell lung cancer and pancreatic cancer. We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Weitian Liu, Frederick L. Makrauer, Amir A. Qamar, Pasi A. Jänne, Robert D. Odze,